Phone: (+39) 0813995453


Application of bidirectional telemedicine in home CPAP for children with obstructive sleep apnea syndrome

HumanInsight Application of bidirectional telemedicine in home CPAP for children with obstructive sleep apnea syndrome

Int J Pediatr Otorhinolaryngol. 2024 Jul 25;183:112047. doi: 10.1016/j.ijporl.2024.112047. Online ahead of print.

ABSTRACT

BACKGROUND: Traditional telemedicine follow-up proves unsuitable for home continuous positive airway pressure (CPAP) therapy in children with obstructive sleep apnea syndrome (OSAS). Accompanying advancements in mobile internet, this study explores the feasibility and effectiveness of a mobile communication and remote monitoring system as a novel bidirectional telemedicine approach to enhance adherence to home CPAP in children with OSAS.

METHODS: A prospective cohort utilizing bidirectional telemedicine follow-up from January to December 2022 (TM) was compared with a retrospective cohort receiving conventional phone follow-up from August 2018 to December 2021 (CP). Participants in TM group were subdivided into two groups based on the number of inquiries in the first week: a high-question group and a low-question group. The main endpoints included successful CPAP adaption and adherence at 2 months of follow-up.

RESULTS: The TM group exhibited a significantly lower termination rate within 2 months compared to the CP group (1/24 vs. 6/22, p = 0.037). In the first week of home CPAP, the high-question group reported shorter average nightly usage and fewer days with usage of ≥4 h compared to the low-question group (5 h per night vs. 8.5 h per night, 4.5 days vs. 7 days, both p < 0.001). However, the high-question group showed significant improvement in adherence from the second week onward for the remainder of the study period.

CONCLUSIONS: Bidirectional telemedicine represents an effective and feasible method to improve adherence to home CPAP therapy in children with OSAS. Considering the costs, researchers recommend applying bidirectional telemedicine for at least 1 week to better enhance long-term adherence.

PMID:39068707 | DOI:10.1016/j.ijporl.2024.112047

Powered by WPeMatico

P.IVA 08738511214
Privacy Policy
Cookie Policy

Sede Legale
Viale Campi Flegrei 55
80124 - Napoli

Sede Operativa
Via G.Porzio 4
Centro Direzionale G1
80143 - Napoli

ISO9001
AI 4394
© Copyright 2022 - Humaninsight Srls - All Rights Reserved
Privacy Policy | Cookie Policy
envelopephone-handsetmap-marker linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram